ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21

Cancer Research

Volumn 70, Issue 8, 2010, Pages 3239-3248

  Geng, Hao ^a   Rademacher, Brooks L ^a   Pittsenbarger, Janet ^a   Huang, Chung Ying ^b   Harvey, Christopher T ^a   Lafortune, Marie C ^a   Myrthue, Anne ^a   Garzotto, Mark ^a   Nelson, Peter S ^b   Beer, Tomasz M ^a   Qian, David Z ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DOCETAXEL; INHIBITOR OF DIFFERENTIATION 1; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN P21; SERINE; SMALL INTERFERING RNA;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER RELAPSE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRAIN LNCAP; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; E BOX ELEMENT; ENZYME ACTIVATION; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MALE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TAXOIDS;

EID: 77951067216     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3186     Document Type: Article

References (50)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512 (Pubitemid 39315317)
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245
3. Mackler NJ, Pienta KJ. Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2005;2:92-100; quiz 1 p following 12.
4. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-5240 (Pubitemid 41003711)
5. Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24:254-259
6. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007;110:1248-1254 (Pubitemid 47435595)
7. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. Cancer Cell 2003;3:525-530
8. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene 2001;20:8334-8341
9. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001;20:8326-8333
10. Caldon CE, Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 2008;68:3026-3036 (Pubitemid 351556304)
11. Alani RM, Young AZ, Shifflett CB. Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci U S A 2001;98:7812-7816
12. Ciarrocchi A, Jankovic V, Shaked Y, et al. Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS ONE 2007;2:e1338. (Pubitemid 351736606)
13. Everly DN, Jr., Mainou BA, Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol 2004;78:13470-13478 (Pubitemid 39612747)
14. Hara E, Yamaguchi T, Nojima H, et al. Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J Biol Chem 1994;269:2139-2145 (Pubitemid 24035425)
15. Kim D, Peng XC, Sun XH. Massive apoptosis of thymocytes in T-cell-deficient Id1 transgenic mice. Mol Cell Biol 1999;19:8240-8253 (Pubitemid 30414018)
16. Parrinello S, Lin CQ, Murata K, et al. Id-1, ITF-2, and Id-2 comprise a network of helix-loop-helix proteins that regulate mammary epithelial cell proliferation, differentiation, and apoptosis. J Biol Chem 2001;276:39213-39219 (Pubitemid 37371294)
17. Tanaka K, Pracyk JB, Takeda K, et al. Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism. J Biol Chem 1998;273:25922-25928 (Pubitemid 28475823)
18. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-1201 (Pubitemid 33063774)
19. Sikder H, Huso DL, Zhang H, et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003;4:291-299 (Pubitemid 37329793)
20. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-524
21. Gupta GP, Perk J, Acharyya S, et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A 2007;104:19506-19511
22. Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis 2004;25:517-525 (Pubitemid 38499942)
23. Ling MT, Wang X, Ouyang XS, et al. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene 2002;21:8498-8505 (Pubitemid 36054890)
24. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC. Id-1 expression promotes cell survival through activation of NF-κB signalling pathway in prostate cancer cells. Oncogene 2003;22:4498-4508 (Pubitemid 36920693)
25. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 2005;174:2022-2026
26. Di K, Ling MT, Tsao SW, Wong YC, Wang X. Id-1 modulates senescence and TGF-β1 sensitivity in prostate epithelial cells. Biol Cell 2006;98:523-533 (Pubitemid 44383369)
27. Zhang X, Ling MT, Wang X, Wong YC. Inactivation of Id-1 in prostate cancer cells: a potential therapeutic target in inducing chemosensitization to Taxol through activation of JNK pathway. Int J Cancer 2006;118:2072-2081
28. Zhang X, Ling MT, Wang Q, et al. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem 2007;282:33284-33294 (Pubitemid 350159546)
29. Perk J, Gil-Bazo I, Chin Y, et al. Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res 2006;66:10870-10877 (Pubitemid 44876984)
30. Qian DZ, Huang CY, O'Brien CA, et al. Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res 2009;15:3135-3142
31. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 2007;67:1182-1193 (Pubitemid 47221885)
32. Myrthue A, Rademacher BL, Pittsenbarger J, et al. The iroquois homeobox Gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells. Clin Cancer Res 2008;14:3562-3570
33. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007;27:7381-7393 (Pubitemid 350033646)
34. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2004;64:6626-6634 (Pubitemid 39297923)
35. Huang CY, Beer TM, Higano CS, et al. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007;13:5825-5833
36. Lin DW, Coleman IM, Hawley S, et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol 2006;24:3763-3770 (Pubitemid 46622315)
37. Swarbrick A, Akerfeldt MC, Lee CS, et al. Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene 2005;24:381-389 (Pubitemid 40188586)
38. Zeller KI, Zhao X, Lee CW, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 2006;103:17834-17839 (Pubitemid 44852246)
39. Basu A, Haldar S. Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 1998;13:659-664 (Pubitemid 28435339)
40. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-5190
41. 2 arrest after DNA damage. Science 1998;282:1497-1501
42. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269
43. Verheul HM, Qian DZ, Carducci MA, Pili R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol 2007;60:329-339 (Pubitemid 46944585)
44. Zhan J, Easton JB, Huang S, et al. Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol 2007;27:3530-3541 (Pubitemid 46685227)
45. Wang TH, Wang HS, Ichijo H, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998;273:4928-4936 (Pubitemid 28108645)
46. Mhaidat NM, Zhang XD, Jiang CC, Hersey P. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 2007;13:1308-1314 (Pubitemid 46424072)
47. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002;419:729-734 (Pubitemid 35177959)
48. Hernandez-Vargas H, Ballestar E, Carmona-Saez P, et al. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 2006;119:1164-1175 (Pubitemid 44121416)
49. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of ID-1 in prostate cancer. J Urol 2002;167:2598-2602
50. Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY. Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res 2004;10:2044-2051 (Pubitemid 38375565)